At the recent Association for Research in Vision and Ophthalmology meeting, results of a study on R-Tech Ueno's unoprostone (development code UF-021) for retinitis pigmentosa were announced.More »
Patient enrollment has begun in the confirmatory Phase III clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain following cataract surgery.More »
Eleven Biotherapeutics recently presented data for EBI-005, the first interleukin-1 (IL-1) signaling inhibitor designed for topical ocular administration.More »
R-Tech Ueno is developing a recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) for the treatment of severe dry eye.More »
In the past several years, new research has given us a much better understanding of dry eye disease, leading to a number of exciting clinical advances in the evaluation and treatment of this chronic cMore »
Alcon recently reported that the FDA approved its Simbrinza Suspension, which is indicated for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or oculMore »
TALLAHASSEE, Fla.—Florida Governor Rick Scott signed Florida Senate Bill 278 on Friday, April 19, authorizing optometrists in that state to prescribe ocular pharmaceutical agents.More »
